Inhibition of IFN signaling with the anti-IFNAR1 antibody anifrolumab has produced clinical improvement in SLE and received regulatory approval, demonstrating that IFN activity drives pathology in at least a subset of patients [176]. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.